At Dennis Partners, we know regulatory recruiting. We are committed to creating and maintaining partnerships with our clients while upholding the highest standards of professionalism and ethics. Our team interacts within the marketplace on a daily basis, giving us the ability to locate, screen, and recommend exceptional individuals to your firm. We know how to identify the top performers. Our strength is partnering with you and your business to develop a solution and meet demands for growth while improving efficiency. Let our advanced expertise find the top professionals in the industry to provide a competitive edge to your company.
We have your specialization covered
Contract-to-hire evaluation process
We're on your side
Complete back office support
Our process is cost-effective
Dennis Partner’s focus on only regulatory affairs searches gives them a very good sense of the market, the available talent, and who matches the role. They worked with us diligently to find the right candidate and we ended up making an exceptional hire.
We take the time to evaluate your needs beyond a job description
We identify top talent from our research and competitive analysis
We analyze the talent to match candidates on a deeper level
We go beyond the hire by offering extensive post placement services
Does your company have immediate top-tier talent needs?
Meet Our Team
Hi folks, I am publishing my blog a day early due to the holiday weekend. Here are the top regulatory stories for this week: On Monday Dova Pharmaceuticals announced the FDA completed their Priority Review and approved DOPTELET (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to[…]
This was a big week with the approval of three new molecular entities by the FDA while Evolus received a complete response letter. Here is my recap of the top regulatory news stories this week: The FDA approved Amgen’s Aimovig (erenumab-aooe) for the preventive treatment of migraines in adults: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm The FDA approved Pfizer’s Retacrit (epoetin[…]
It is 3pm and you’re asking yourself, “Where did the day go?” You’ve only gotten halfway through your task list, and you’re wondering how this is possible when you carefully prepared your daily goals. Everything had been planned and prioritized, yet something has robbed valuable hours of your day. A Salary.com survey showed that 60%[…]
The FDA approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. http://www.pharmacytimes.com/news/fda-approves-drug-combination-for-treating-brafpositive-anaplastic-thyroid-cancer The FDA has promised Roche/Genentech a priority review for Tecentriq plus Avastin and chemo for lung cancer, with[…]
This was a pretty busy week with an approval of a new molecular entity for Portola, a second indication approval for Novartis’s Kymriah, several new orphan drug designations, and a complete response letter for Sandoz. Here are the top regulatory news stories for this week: Portola Pharmaceuticals received FDA accelerated approval for once-rejected Andexxa, the[…]
What’s your reaction when you hear a 5-time Super Bowl winning quarterback state he feels everyone could be more appreciated? Part of it depends on whether you’re a Patriots fan, but let’s take that out of the equation. As an employer, it hit me like a ton of bricks because Tom Brady is one of[…]
The FDA has approved Helsinn’s intravenous formulation of AKYNZEO® (a fixed antiemetic combination of fosnetupitant and palonosetron) as an alternative treatment option for patients experiencing Chemotherapy Induced Nausea and Vomiting. Oral AKYNZEO® was previously approved by the FDA as a fixed combination oral agent in 2014. https://www.helsinn.com/news-and-events/helsinn-group-announces-the-fda-approval-of-the-iv-formulation-of-akynzeo-fosnetupitant-palonosetron-in-the-united-states/ Catalyst Pharmaceuticals announced its submission of a NDA[…]
Rigel Pharmaceuticals announced that the FDA approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. https://www.prnewswire.com/news-releases/rigel-announces-fda-approval-of-tavalisse-fostamatinib-disodium-hexahydrate-for-chronic-immune-thrombocytopenia-itp-in-adult-patients-300631702.html Ultragenyx and Kyowa Kirin announced FDA approval of Crysvita® (burosumab-twza) for the treatment of children and adults with X–Linked Hypophosphatemia http://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-kyowa-kirin-announce-fda-approval-crysvitar[…]
In the process of planning your next Strategic Career Move, the value of Interview Preparation can never be taken lightly. Too often I find myself explaining to candidates the importance of being fully prepared for an interview. This preparation is paramount to your success, no matter what the position or level may be. On the[…]
This was a relatively busy week with new draft guidances, new orphan drug designations, two supplemental approvals, and the lifting of a clinical hold. Here are the top regulatory stories for this week: The Food and Drug Administration has approved the first artificial intelligence software that can decide, without a clinician’s involvement, whether a patient[…]